# Lantheus Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Lantheus Holdings, Inc.).

## Overview

Lantheus Holdings, Inc. develops and commercializes diagnostic imaging agents used in nuclear medicine, with a portfolio centered on PET radiodiagnostics, ultrasound contrast agents, and selected legacy SPECT products. The company’s business is built around products that help clinicians detect and characterize disease, especially in oncology, cardiology, and neurology, and it also earns royalties and milestone payments from licensed products.

## Products & services

• PYLARIFY PSMA PET imaging agent for prostate cancer
• DEFINITY ultrasound enhancing agent for echocardiography
• Neuraceq amyloid PET imaging agent for Alzheimer’s evaluation
• Legacy SPECT products: TechneLite, NEUROLITE, Xenon Xe-133 Gas, Cardiolite
• Flyrcado licensed PET radiodiagnostic with royalty/milestone economics
• Contract manufacturing services and radiopharmaceutical capabilities

- **PET radiodiagnostics** (60%) — PET imaging agents used to detect and stage disease, including prostate cancer and amyloid imaging.
- **Ultrasound contrast agents** (20%) — Microbubble-based agents used to improve echocardiography image quality and cardiac assessment.
- **SPECT diagnostics** (10%) — Legacy single-photon imaging products used in nuclear medicine procedures and hospital workflows.
- **Licensed products and royalties** (5%) — Economics from licensed assets such as Flyrcado, including milestone and royalty payments.
- **Contract manufacturing and services** (5%) — Manufacturing services and related radiopharmaceutical production capabilities for third parties.

- PYLARIFY PSMA PET imaging agent for prostate cancer
- DEFINITY ultrasound enhancing agent for echocardiography
- Neuraceq amyloid PET imaging agent for Alzheimer’s evaluation
- Legacy SPECT products: TechneLite, NEUROLITE, Xenon Xe-133 Gas, Cardiolite
- Flyrcado licensed PET radiodiagnostic with royalty/milestone economics
- Contract manufacturing services and radiopharmaceutical capabilities

## Customers

Lantheus sells primarily to hospitals, imaging centers, nuclear medicine departments, and physician practices that perform diagnostic scans. Its products are bought by clinicians and healthcare systems because they improve visualization, support diagnosis, and help guide treatment decisions in oncology, cardiology, and neurology.

- **Hospitals and integrated health systems** (primary) — Buy imaging agents for routine and specialized diagnostic workflows across nuclear medicine and echocardiography.
- **Outpatient imaging centers** (primary) — Purchase PET and ultrasound contrast products to support high-throughput diagnostic scans.
- **Cardiology practices** (secondary) — Use DEFINITY to improve endocardial border definition and diagnostic confidence in echocardiograms.
- **Oncology and urology providers** (primary) — Use PYLARIFY to detect PSMA-positive prostate cancer lesions and support treatment planning.
- **Neurology and memory care providers** (secondary) — Use Neuraceq for amyloid PET imaging when evaluating patients for Alzheimer’s disease.

- Hospitals and health systems performing PET, SPECT, and echo studies
- Imaging centers and nuclear medicine departments needing diagnostic tracers
- Cardiologists using DEFINITY to improve echocardiography image quality
- Oncologists and urologists using PYLARIFY for prostate cancer imaging
- Neurology and memory clinics using amyloid PET to assess Alzheimer’s disease

## Geography

Lantheus is headquartered in Massachusetts and operates with offices in New Jersey, Canada, Germany, Switzerland, Sweden, and the United Kingdom. The company’s business is global in distribution and regulatory reach, but the disclosed reports emphasize a U.S.-centered operating base with international commercial and support locations rather than a country revenue split.

- Headquartered in Massachusetts, with a key production footprint in North Billerica
- U.S. market is central because most products are sold into American healthcare systems
- International offices in Canada, Germany, Switzerland, Sweden, and the UK support sales
- European presence matters for licensing, commercialization, and regulatory execution
- Canadian operations were part of the SPECT business sold to SHINE in 2026

## Strategy

Lantheus is narrowing its portfolio toward higher-growth radiopharmaceuticals and PET diagnostics after selling its SPECT business in 2026. Management is also investing in lifecycle management, clinical development, and partnerships to extend the commercial life of core assets while building the next wave of imaging products.

- **Reposition the portfolio toward PET radiodiagnostics** (short-term) — The SPECT sale simplifies the business and concentrates resources on higher-growth imaging categories.
- **Protect PYLARIFY’s commercial franchise** (short-term) — PYLARIFY is a major revenue driver and faces reimbursement, manufacturing, and competition risks.
- **Expand through partnerships and licensing** (medium-term) — Licensing can extend reach without full internal commercialization costs.
- **Build the next pipeline of radiopharmaceutical assets** (medium-term) — New products are needed to offset exclusivity expiry and sustain growth.

- Focus on PET radiodiagnostics and microbubbles after SPECT divestiture
- Defend and expand PYLARIFY through access, promotion, and differentiation
- Grow Neuraceq and other PET assets through commercial execution
- Use licensing and partnerships to monetize assets like Flyrcado
- Pursue clinical development and lifecycle management opportunities

## Risks

The company depends heavily on a small number of imaging products, especially PYLARIFY, so reimbursement changes, competitive launches, or loss of exclusivity could materially affect revenue. Manufacturing reliability, supply chain continuity, and regulatory compliance are also critical because these products require specialized production and distribution infrastructure.

- **PYLARIFY commercial concentration** [high] — A substantial share of revenue depends on one product and its reimbursement/access profile.
- **Competition and loss of exclusivity** [high] — Competitors already market or are developing alternative PET agents and ultrasound products.
- **Manufacturing and supply chain disruption** [high] — Radiopharmaceutical production is time-sensitive and depends on specialized facilities and inputs.
- **Regulatory and reimbursement changes** [high] — Coverage, coding, and payment decisions directly affect adoption and net sales.
- **Cybersecurity and AI operational risk** [medium] — Digital systems support research, manufacturing, and commercialization, creating attack and error exposure.

- PYLARIFY concentration risk if demand, reimbursement, or access weakens
- Competition from larger imaging and radiopharma companies
- Manufacturing or supply disruptions at PMFs or third-party suppliers
- Potential generic or follow-on competition after exclusivity expiry
- Cybersecurity and AI-related operational risks

## Accounting

Revenue recognition is driven by transfer of control for products and services, but reported net sales are heavily affected by rebates, allowances, distributor fees, and government programs. Investors should also watch acquisition accounting, fair value marks, and contingent items because recent deals and licensing arrangements can move earnings and cash flow materially.

- **Revenue recognition and rebate accruals** — Can materially change reported revenue and receivables
- **Acquisition accounting** — Affects goodwill, amortization, and operating expenses
- **Seasonality** — Quarterly comparability and working capital swings
- **Asset retirement and facility assurance** — Relevant to contingent obligations and facility-related estimates

- Revenue net of rebates and allowances reduces reported sales
- Product sales are recognized when control transfers to customers
- Acquisitions create fair value estimates and amortization expense
- Seasonality can shift procedure timing across quarters
- Contingent liabilities and asset retirement obligations affect estimates

---

*Last updated: 2026-04-28T20:22:18.799736+00:00*